2013-02-07 20:03:19 -
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/07/13 -- Verisante Technology, Inc. : www.verisante.com/
(TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has won a 2013 Prism Award in the Life Sciences and Biophotonics category for Aura(TM), a revolutionary skin cancer detection device. The winners were announced at an Awards banquet on February 6, 2013 in San Francisco.
"It is very gratifying to be recognized as an industry leader for our innovative and disruptive technology," said Thomas Braun, the Company's President & CEO, who accepted the award on behalf of the Company. "Many years of hard work and scientific research have contributed to this honour, and we would like to recognize the dedication of the BC Cancer Agency, the Skin Care Centre at Vancouver General Hospital, the University of British Columbia and the Vancouver Coastal Health Research Institute, whose collaboration in the development of this technology provided Verisante with the opportunity to bring Aura(TM) to full commercialization."
First sales of Aura(TM) were recently announced : verisante.com/news/98/verisante-technology-inc-announces-first-s ..
through the Company's exclusive distributors, Clarion Medical Technologies : www.clarionmedical.com/aestheticmedicaltech/verisante_aura.html
in Canada, and bo pharma : www.bo-pharma.com/huidkanker/verisante/
and Laserwelt : www.laserwelt.com/en/sale/verisante/aura/
in Europe. The Company expects to begin placing the first nine of the initial production units that have been sold in clinics across Canada and Europe in the next several weeks. The Company will keep the remaining unit for demonstration purposes at its head office in Vancouver.
Verisante Aura(TM) is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura(TM) is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
To view photos from the Prism Awards ceremony, visit Verisante's Facebook page at: www.facebook.com/verisante
About the 2013 Prism Awards
The Prism Awards, named the "Photonics Oscar" by OptecNet Deutschland, is a celebration of the best of our industry. It takes place every year in conjunction with SPIE Photonics West in San Francisco, California.
The Prism Awards for Photonics Innovation is a leading international competition that honors the best new photonic products on the market. Over the years, the Prism Awards has received applications from more than 35 countries across the globe. Applications are judged by a panel of leading industry experts, venture capitalists, luminaries and visionaries. The finalists and winners that are ultimately chosen (from General Electric, Agilent, Hamamatsu to Swamp Optics, Optotune, WiTec) reflect the diversity of the program.
SPIE Photonics West is the world's largest and most influential photonics and optics event with over 1500 companies exhibiting and 20,000 attendees.
To find out more about the Awards, visit the website at: www.photonicsprismaward.com
About Verisante Technology, Inc.
Verisante is a medical device company : www.verisante.com/about/
committed to commercializing innovative systems for the early detection of cancer : www.verisante.com/
. The Verisante Aura(TM) for skin cancer detection : www.verisante.com/products/aura/
and the Verisante Core(TM) series for lung, colon and cervical cancer detection : www.verisante.com/products/core/
utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results : www.verisante.com/products/aura/
for many of the most common cancers. Aura(TM) has been approved for sale in Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.
Verisante Aura(TM) was awarded Popular Science Magazine's " Best of What's New Award : www.popsci.com/bown/2011/product/verisante-aura
" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs : verisante.com/news/72/canadian-cancer-society-names-verisante-co ..
of 2011 by the Canadian Cancer Society.
Website: www.verisante.com : www.verisante.com/
YouTube: www.youtube.com/verisante : www.youtube.com/verisante
Twitter: www.twitter.com/verisante : www.twitter.com/verisante
Facebook: www.facebook.com/verisante : www.facebook.com/verisante
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Verisante Technology, Inc.
President & CEO
(604) 605-0507 email@example.com
at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid= .. width="1" height="1" alt=" " border="0" />